Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Geneva, Switzerland and Boston, MA – Thursday 11 February, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and...
-
Geneva, Switzerland and Boston, MA – Thursday 28 January, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and...
-
-
-
Geneva, Switzerland and Boston, MA – Tuesday 14, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
-
Samkvæmt 84. gr. laga um verðbréfaviðskipti nr. 108/2007 skal útgefandi, ef hann hækkar eða lækkar hlutafé sitt eða fjölgar eða fækkar atkvæðum, á síðasta viðskiptadegi þess mánaðar er breytingarnar...
-
According to Article 84 of Act No. 108/2007 on Securities transactions, when an issuer increases or reduces its share capital or number of voting rights, the issuer shall on the last trading day of...
-
Samkvæmt 84. gr. laga um verðbréfaviðskipti nr. 108/2007 skal útgefandi, ef hann hækkar eða lækkar hlutafé sitt eða fjölgar eða fækkar atkvæðum, á síðasta viðskiptadegi þess mánaðar er breytingarnar...
-
According to Article 84 of Act No. 108/2007 on Securities transactions, when an issuer increases or reduces its share capital or number of voting rights, the issuer shall on the last trading day of...
-
Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...